Last reviewed · How we verify
NCT04481763
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Phase 1, PHASE2 trial testing Camrelizumab in Triple-Negative Breast Cancer in 20 participants. Currently enrolling.
30 August 2024
Quick facts
| Lead sponsor | Jiangxi Provincial Cancer Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 14 July 2020 |
| Primary completion | 30 August 2024 |
| Estimated completion | 1 October 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab — full drug profile →
- radiotherapy — full drug profile →
Conditions studied
- Triple-Negative Breast Cancer — all drugs for Triple-Negative Breast Cancer →
Sponsor
Jiangxi Provincial Cancer Hospital
Who can join
Adults 18 to 75, female only, with Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC。
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance.
Bai X, Ni J, Beretov J, Graham P, et al · · 2021 · cited 33× · PMID 39036372 · DOI 10.1016/j.jncc.2021.06.001 -
Immunotherapy for Triple-Negative Breast Cancer.
Cao Y, Chen C, Tao Y, Lin W, et al · · 2021 · cited 17× · PMID 34959285 · DOI 10.3390/pharmaceutics13122003 -
Mechanisms of radioresistance and radiosensitization strategies for Triple Negative Breast Cancer.
Wang Y, Liu Z, Lv Y, Long J, et al · · 2025 · cited 8× · PMID 40112501 · DOI 10.1016/j.tranon.2025.102351 -
Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review.
Xu RC, Zhang YW, Liu CC, Xu YY, et al · · 2025 · cited 3× · PMID 40443538 · DOI 10.1016/j.lanwpc.2024.101180
Verify or expand the search:
- PubMed search for NCT04481763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Camrelizumab
Trials testing the same drug.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
- NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
- NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting
Other recruiting trials for Triple-Negative Breast Cancer
Currently open trials in the same condition.
- NCT07525869 — An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Pa · NA · recruiting
- NCT07104266 — Triple Negative Breast Cancer and Celecoxib. Pilot Study · Phase 2 · recruiting
- NCT06393374 — Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · Phase 3 · recruiting
- NCT05806060 — Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer · Phase 3 · recruiting
- NCT05760378 — Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or M · Phase 3 · recruiting
Other Jiangxi Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07314255 — The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma · active not recruiting
- NCT07277764 — Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc · Phase 2 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
- NCT07085988 — Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT06770699 — Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04481763 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangxi Provincial Cancer Hospital
- Last refreshed: 22 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04481763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing